<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26046796</article-id><article-id pub-id-type="pmc">4627242</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Paper</subject></subj-group></article-categories><title-group><article-title>Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Jack P.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Chen-Yi</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yeh</surname><given-names>Yi-Cheng</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shyr</surname><given-names>Yi-Ming</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Ying-Ying</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuo</surname><given-names>Chen-Yu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A9"><sup>9</sup></xref><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hung</surname><given-names>Yi-Ping</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ming-Huang</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Wei-Ping</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Jiing-Chyuan</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chao</surname><given-names>Yee</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A12"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Chung-Pin</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan</aff><aff id="A2"><sup>2</sup> National Yang-Ming University School of Medicine, Taipei, Taiwan</aff><aff id="A3"><sup>3</sup> Division of Gastroenterology, Department of Internal Medicine, Renai Branch, Taipei City Hospital, Taipei, Taiwan</aff><aff id="A4"><sup>4</sup> Institute of Public Health, National Yang-Ming University, Taipei, Taiwan</aff><aff id="A5"><sup>5</sup> Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan</aff><aff id="A6"><sup>6</sup> Department of Dermatology, Heping Fuyou Branch, Taipei City Hospital, Taipei, Taiwan</aff><aff id="A7"><sup>7</sup> Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan</aff><aff id="A8"><sup>8</sup> Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan</aff><aff id="A9"><sup>9</sup> Department of Medicine, National Yang-Ming University Hospital, Yilan, Taiwan</aff><aff id="A10"><sup>10</sup> Division of Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan</aff><aff id="A11"><sup>11</sup> Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan</aff><aff id="A12"><sup>12</sup> Department of Oncology Medicine, Taipei Veterans General Hospital, Taipei, Taiwan</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Chung-Pin Li,</italic><email>cpli@vghtpe.gov.tw</email></corresp></author-notes><pub-date pub-type="collection"><day>20</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>20</day><month>5</month><year>2015</year></pub-date><volume>6</volume><issue>20</issue><fpage>18162</fpage><lpage>18173</lpage><history><date date-type="received"><day>18</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Wang et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic cancer, and to determine the predictive role of epidermal growth factor receptor (<italic>EGFR</italic>) and <italic>KRAS</italic> mutations in these patients.</p></sec><sec><title>Methods</title><p>This was a single-center, randomized, open-label, prospective trial. Eighty-eight chemotherapy-na&#x000ef;ve metastatic pancreatic cancer patients were randomized for treatment with gemcitabine or gemcitabine plus erlotinib. <italic>EGFR</italic> and <italic>KRAS</italic> mutations were analyzed, respectively. The primary endpoint was the disease control rate.</p></sec><sec><title>Results</title><p>Disease control rate (64% <italic>vs.</italic> 25%; <italic>P</italic> &#x0003c; 0.001), progression-free survival (median 3.8 <italic>vs.</italic> 2.4 months; <italic>P</italic> &#x0003c; 0.001), and overall survival (median 7.2 <italic>vs.</italic> 4.4 months; <italic>P</italic> &#x0003c; 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% <italic>vs.</italic> 33%; <italic>P</italic> = 0.001), progression-free survival (median 5.9 <italic>vs</italic>. 2.4 months; <italic>P</italic> = 0.004), and overall survival (median 8.7 <italic>vs</italic>. 6.0 months; <italic>P</italic> = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival.</p></sec><sec><title>Conclusions</title><p>Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with <italic>EGFR</italic> mutations. <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> number, NCT01608841.</p></sec></abstract><kwd-group><kwd>adenocarcinoma</kwd><kwd>pancreas</kwd><kwd>erlotinib</kwd><kwd>epidermal growth factor receptor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Pancreatic cancer is a rapidly progressive malignancy with a 5-year survival rate of &#x0003c;10% [<xref rid="R1" ref-type="bibr">1</xref>]. Gemcitabine is the standard chemotherapy for metastatic pancreatic adenocarcinoma, but shows an objective response rate of only 5&#x02013;10% and a median survival of 5.7&#x02013;6.8 months [<xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R5" ref-type="bibr">5</xref>]. During the last decade, many trials have been conducted on combined treatment with gemcitabine and targeted agents in an attempt to improve treatment outcome [<xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R8" ref-type="bibr">8</xref>]. Unfortunately, most trials have failed to demonstrate any survival benefit compared to gemcitabine alone.</p><p>The mutation status of the <italic>EGFR</italic> tyrosine kinase (TK) domain is a predictive factor for EGFR inhibitor therapy in non-small cell lung cancer (NSCLC), especially among the Chinese people [<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R14" ref-type="bibr">14</xref>]. Whether this result applies to pancreatic cancer remains unclear. Erlotinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is an orally active agent for advanced NSCLC and pancreatic cancer [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R15" ref-type="bibr">15</xref>]. The phase III NCIC CTG PA.3 trial comparing gemcitabine plus erlotinib and gemcitabine alone in advanced pancreatic cancer is the only trial of a targeted agent in pancreatic cancer that has shown a statistically significant improvement in survival [<xref rid="R3" ref-type="bibr">3</xref>]. However, the survival was only slightly longer for the gemcitabine plus erlotinib arm versus the gemcitabine plus placebo arm (median 6.24 <italic>vs</italic>. 5.91 months, <italic>P</italic> = 0.038). Considering cost effectiveness and the survival benefit, it is important to be able to accurately select the subgroup of patients who could benefit from this therapeutic regimen.</p><p>Pancreatic cancer shows the highest frequency of <italic>KRAS</italic> gene mutations among human cancers [<xref rid="R16" ref-type="bibr">16</xref>]. Ras signaling pathways are commonly activated in tumors and are involved in mediating the downstream effects of <italic>EGFR</italic> activation. Greater than 95% of these mutations involve codon 12 or 13 (exon 2), and a few involve codon 61 (exon 3) [<xref rid="R16" ref-type="bibr">16</xref>]. Whether <italic>KRAS</italic> mutations are associated with less efficient <italic>EGFR</italic>-directed targeted therapy in pancreatic cancer patients remains controversial and requires further investigation [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>].</p><p>To clarify the effects of adding erlotinib to gemcitabine and the roles of <italic>EGFR</italic> and <italic>KRAS</italic> mutations as predictive biomarkers in patients with advanced pancreatic cancer who receive these regimens, we performed this open-label, randomized, prospective study.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Patient characteristics</title><p>Between July 2005 and June 2012, 88 patients were randomly assigned (44 gemcitabine plus erlotinib and 44 gemcitabine alone) (Figure <xref ref-type="fig" rid="F1">1</xref>). Baseline characteristics (Table <xref ref-type="table" rid="T1">1</xref>) were well matched between the gemcitabine plus erlotinib arm and the gemcitabine alone arm. The median follow-up time was 7.2 months (range, 0.1&#x02013;30.5 months) for the gemcitabine plus erlotinib group and 4.5 months (range, 0.4&#x02013;16.9 months) for the gemcitabine alone group.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>CONSORT diagram</title></caption><graphic xlink:href="oncotarget-06-18162-g001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patient characteristics</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Characteristics</th><th rowspan="2" align="left" valign="top" colspan="1">All patients(n = 88)</th><th colspan="2" align="center" valign="top" rowspan="1">Gemcitabine alone (n = 44)</th><th colspan="2" align="center" valign="top" rowspan="1">Gemcitabine + erlotinib (n = 44)</th><th rowspan="2" align="center" valign="middle" colspan="1">P</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1"><italic>EGFR</italic> Mutation (+) (n = 23)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>EGFR</italic> Mutation (&#x02212;) (n = 21)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>EGFR</italic> Mutation (+) (n = 26)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>EGFR</italic> Mutation (&#x02212;) (n = 18)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.711</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Male</td><td align="center" valign="top" rowspan="1" colspan="1">65 (74%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (70%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (81%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (77%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (67%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Female</td><td align="center" valign="top" rowspan="1" colspan="1">23 (26%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (30%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (33%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (Years)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.160</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Median</td><td align="center" valign="top" rowspan="1" colspan="1">70</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">74</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">65</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Range</td><td align="center" valign="top" rowspan="1" colspan="1">33&#x02013;91</td><td align="center" valign="top" rowspan="1" colspan="1">37&#x02013;86</td><td align="center" valign="top" rowspan="1" colspan="1">33&#x02013;91</td><td align="center" valign="top" rowspan="1" colspan="1">35&#x02013;86</td><td align="center" valign="top" rowspan="1" colspan="1">43&#x02013;84</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Performance status</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.057</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;0</td><td align="center" valign="top" rowspan="1" colspan="1">73 (83%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (87%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (76%)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (81%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (89%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;1</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (13%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (24%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (11%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Relapse after surgery</td><td align="center" valign="top" rowspan="1" colspan="1">20 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (17%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (33%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (22%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.593</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metastatic site</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Liver</td><td align="center" valign="top" rowspan="1" colspan="1">61 (69%)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (83%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (67%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (65%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (61%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.434</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Peritoneum</td><td align="center" valign="top" rowspan="1" colspan="1">49 (56%)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (65%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (48%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (65%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (39%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.217</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Lung</td><td align="center" valign="top" rowspan="1" colspan="1">18 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (9%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (24%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (28%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.423</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Adrenal gland</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.414</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Bone</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (5%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.609</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Others</td><td align="center" valign="top" rowspan="1" colspan="1">9 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (13%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (8%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (11%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.939</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Differentiation</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.479</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Well</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (6%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Moderately</td><td align="center" valign="top" rowspan="1" colspan="1">18 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (26%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (29%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (8%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (22%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Poorly</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (17%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (8%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">55 (63%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (57%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (52%)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (81%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (56%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CA19-9 (U/ml)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Elevated (&#x0003e; 37)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (81%)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (83%)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (90%)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (81%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (67%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.306</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Median (range) in all patients</td><td align="center" valign="top" rowspan="1" colspan="1">1,083 (2&#x02013;1,439,400)</td><td align="center" valign="top" rowspan="1" colspan="1">1,169 (4&#x02013;10,411)</td><td align="center" valign="top" rowspan="1" colspan="1">725 (14&#x02013;97,622)</td><td align="center" valign="top" rowspan="1" colspan="1">1,072 (8&#x02013;439,380)</td><td align="center" valign="top" rowspan="1" colspan="1">1,048 (2&#x02013;1,439,400)</td><td align="center" valign="top" rowspan="1" colspan="1">0.397</td></tr></tbody></table></table-wrap></sec><sec id="s2_2"><title>Response and survival</title><p>The disease control rate (64% <italic>vs</italic>. 25%; <italic>P</italic> &#x0003c; 0.001), PFS (median 3.8 months; 95% confidence interval [CI], 1.2 to 6.4 months <italic>vs</italic>. 2.4 months; 95% CI, 1.9 to 2.9 months; <italic>P</italic> &#x0003c; 0.001), and OS (median 7.2 months; 95% CI, 5.3 to 9.0 months <italic>vs</italic>. 4.4 months; 95% CI, 3.0 to 5.9 months; <italic>P</italic> &#x0003c; 0.001) were significantly better in the gemcitabine plus erlotinib group than in the gemcitabine alone group (Table <xref ref-type="table" rid="T2">2</xref> and Figures <xref ref-type="fig" rid="F2">2A and 2B</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Evaluation of the effect of <italic>EGFR</italic> mutations on treatment response</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1"/><th colspan="3" align="center" valign="top" rowspan="1">Gemcitabine alone</th><th colspan="3" align="center" valign="top" rowspan="1">Gemcitabine + erlotinib</th></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Mutation (+) n = 23</td><td align="center" valign="top" rowspan="1" colspan="1">Mutation (&#x02212;) n = 21</td><td align="center" valign="top" rowspan="1" colspan="1">P</td><td align="center" valign="top" rowspan="1" colspan="1">Mutation (+)n = 26</td><td align="center" valign="top" rowspan="1" colspan="1">Mutation (&#x02212;)n = 18</td><td align="center" valign="top" rowspan="1" colspan="1">P</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Objective response</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Complete response</td><td align="center" valign="top" rowspan="1" colspan="1">0/23 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0/21 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0/26 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0/18 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Partial response</td><td align="center" valign="top" rowspan="1" colspan="1">1/23 (4%)</td><td align="center" valign="top" rowspan="1" colspan="1">3/21 (14%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7/26 (27%)</td><td align="center" valign="top" rowspan="1" colspan="1">1/18 (6%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Stable disease</td><td align="center" valign="top" rowspan="1" colspan="1">4/23 (17%)</td><td align="center" valign="top" rowspan="1" colspan="1">3/21 (14%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">15/26 (58%)</td><td align="center" valign="top" rowspan="1" colspan="1">5/18 (28%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Progression of disease</td><td align="center" valign="top" rowspan="1" colspan="1">16/23 (70%)</td><td align="center" valign="top" rowspan="1" colspan="1">12/21 (57%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2/26 (8%)</td><td align="center" valign="top" rowspan="1" colspan="1">10/18 (56%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Not assessed<xref ref-type="table-fn" rid="tfn-001">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">2/23 (9%)</td><td align="center" valign="top" rowspan="1" colspan="1">3/21 (14%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2/26 (8%)</td><td align="center" valign="top" rowspan="1" colspan="1">2/18 (11%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Response rate</td><td align="center" valign="top" rowspan="1" colspan="1">1/23 (4%)</td><td align="center" valign="top" rowspan="1" colspan="1">3/21 (14%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.335</td><td align="center" valign="top" rowspan="1" colspan="1">7/26 (27%)</td><td align="center" valign="top" rowspan="1" colspan="1">1/18 (6%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disease control rate</td><td align="center" valign="top" rowspan="1" colspan="1">5/23 (22%)</td><td align="center" valign="top" rowspan="1" colspan="1">6/21 (29%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.601</td><td align="center" valign="top" rowspan="1" colspan="1">22/26 (85%)</td><td align="center" valign="top" rowspan="1" colspan="1">6/18 (33%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Best CA19-9 response</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003e; 80% decline</td><td align="center" valign="top" rowspan="1" colspan="1">2/23 (9%)</td><td align="center" valign="top" rowspan="1" colspan="1">4/21 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.403</td><td align="center" valign="top" rowspan="1" colspan="1">6/26 (23%)</td><td align="center" valign="top" rowspan="1" colspan="1">2/18 (11%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.439</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003e; 50% decline</td><td align="center" valign="top" rowspan="1" colspan="1">6/23 (26%)</td><td align="center" valign="top" rowspan="1" colspan="1">6/21 (29%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.853</td><td align="center" valign="top" rowspan="1" colspan="1">15/26 (58%)</td><td align="center" valign="top" rowspan="1" colspan="1">4/18 (22%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td></tr></tbody></table><table-wrap-foot><fn id="tfn-001"><label>*</label><p>Included patients with either early death or symptomatic deterioration but no objective evaluation. Response rate included complete response and partial response. Disease control rate included complete response, partial response, and stable disease.</p></fn></table-wrap-foot></table-wrap><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><bold>A.</bold> Progression-free survival for gemcitabine alone or gemcitabine plus erlotinib. <bold>B.</bold> Overall survival for gemcitabine alone or gemcitabine plus erlotinib. Gem: gemcitabine, Erlot: erlotinib.</p></caption><graphic xlink:href="oncotarget-06-18162-g002"/></fig></sec><sec id="s2_3"><title><italic>EGFR</italic> mutation profile</title><p>Forty-nine (56%) patients had 62 mutations in <italic>EGFR</italic> exons 18&#x02013;21 that caused substantial downstream amino acid changes (activating mutations, <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>). All mutations were heterozygous (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>) and confirmed by next-generation sequencing. Exon 20 was the most commonly mutated exon (50% of the mutations), followed by exon 19 (37%), exon 21 (10%), and exon 18 (3%). L778P in exon 20 was the most common mutation site (24% of all mutations), followed by K728R (19%) and W731X (13%) in exon 19, and I821T (15%) in exon 20. Patients with an L778P mutation who received gemcitabine plus erlotinib had a significantly higher disease control rate than those who received gemcitabine alone (71%, <italic>N</italic> = 7 <italic>vs</italic>. 0%, <italic>N</italic> = 8; <italic>P</italic> = 0.007, <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>).</p><p>Silent mutations were found in 18/88 patients. Six patients had a Q787Q mutation in exon 20, and two of these had additional missense mutations. Four had an F795F mutation, and two of these had other missense mutations. Two had a D800D mutation together with other missense mutations. One had a Q812Q mutation in exon 20 with a simultaneous missense mutation (I821T). Five had a D830D mutation in exon 21, and of these, one had a D830D mutation only. In both the gemcitabine alone and the gemcitabine plus erlotinib groups, response rates, disease control rates, PFS, and OS were not different between patients with silent <italic>EGFR</italic> mutations and patients without mutations. Patients with silent <italic>EGFR</italic> mutations were counted as patients without <italic>EGFR</italic> mutations in this study.</p><p>No activating <italic>EGFR</italic> mutation was found in the buffy coat of all patients, indicating that the mutations occurred somatically during carcinogenesis.</p></sec><sec id="s2_4"><title><italic>EGFR</italic> mutations and tumor response</title><p>In the gemcitabine alone group, response rate, disease control rate, and CA19-9 response rate were comparable between patients with and without <italic>EGFR</italic> mutations (Table <xref ref-type="table" rid="T2">2</xref>). In the gemcitabine plus erlotinib group, patients with <italic>EGFR</italic> mutations had a significantly higher disease control rate (85% vs. 33%; <italic>P</italic> = 0.001) and a significantly higher rate of a &#x0003e;50% CA19-9 decline (58% <italic>vs</italic>. 22%; <italic>P</italic> = 0.020).</p></sec><sec id="s2_5"><title><italic>EGFR</italic> mutations and survival</title><p>Patients receiving gemcitabine alone had similar PFS and OS regardless of the presence of <italic>EGFR</italic> mutations (Figures <xref ref-type="fig" rid="F3">3A</xref> and <xref ref-type="fig" rid="F4">4A</xref>). In the gemcitabine plus erlotinib group, patients with <italic>EGFR</italic> mutations had a significantly longer PFS (5.9 months; 95% CI, 4.5 to 7.3 months <italic>vs</italic>. 2.4 months; 95% CI, 1.5 to 3.3 months; <italic>P</italic> = 0.004, Figure <xref ref-type="fig" rid="F3">3B</xref>) and a significantly longer OS (8.7 months; 95% CI, 6.2 to 11.1 months <italic>vs</italic>. 6.0 months; 95% CI, 3.0 to 8.9 months; <italic>P</italic> = 0.044, Figure <xref ref-type="fig" rid="F4">4B</xref>) than those without <italic>EGFR</italic> mutations.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><bold>Progression-free survival for A.</bold> gemcitabine alone with or without <italic>EGFR</italic> mutations and <bold>B.</bold> gemcitabine plus erlotinib with or without <italic>EGFR</italic> mutations.</p></caption><graphic xlink:href="oncotarget-06-18162-g003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><bold>Overall survival for A.</bold> gemcitabine alone with or without <italic>EGFR</italic> mutations and <bold>B.</bold> gemcitabine plus erlotinib with or without <italic>EGFR</italic> mutations.</p></caption><graphic xlink:href="oncotarget-06-18162-g004"/></fig></sec><sec id="s2_6"><title><italic>KRAS</italic> mutations and treatment response</title><p>Tumor specimens from 83/88 pancreatic adenocarcinomas (94.3%) had a point mutation of <italic>KRAS</italic> in exon 2 or 3. There were 74 mutations in exon 2 (codon 12 or 13), two mutations in exon 3 (codon 61), and seven mutations in both exon 2 and exon 3. <italic>KRAS</italic> mutations were not associated with clinical and pathologic parameters including age, sex, ECOG performance status, tumor location, histologic differentiation, levels of CA19-9, response to chemotherapy, PFS, and OS. Patients with <italic>KRAS</italic> mutations did not have a statistically different rate of <italic>EGFR</italic> mutations (58% <italic>vs</italic>. 20%, <italic>P</italic> = 0.166) compared to patients without KRAS mutations.</p></sec><sec id="s2_7"><title>Toxicity and dosage modifications</title><p>Forty-four patients treated with gemcitabine and erlotinib and 44 treated with gemcitabine alone received at least one dose of study medication and were available for assessment of toxicity. Adverse events are summarized in Table <xref ref-type="table" rid="T3">3</xref>.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Adverse events</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1"/><th colspan="8" align="center" valign="top" rowspan="1">Gemcitabine alone</th><th colspan="8" align="center" valign="top" rowspan="1">Gemcitabine + erlotinib</th></tr><tr><th colspan="4" align="center" valign="top" rowspan="1">Mutation (+) n=23</th><th colspan="4" align="center" valign="top" rowspan="1">Mutation (&#x02212;) n=21</th><th colspan="4" align="center" valign="top" rowspan="1">Mutation (+) n=26</th><th colspan="5" align="center" valign="top" rowspan="1">Mutation (&#x02212;) n=18</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Grade</th><th align="center" valign="top" rowspan="1" colspan="1">1</th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="center" valign="top" rowspan="1" colspan="1">3</th><th align="center" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">1</th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="center" valign="top" rowspan="1" colspan="1">3</th><th align="center" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">1</th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="center" valign="top" rowspan="1" colspan="1">3</th><th align="center" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">1</th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="center" valign="top" rowspan="1" colspan="1">3</th><th align="center" valign="top" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Haematological</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Leucopoenia</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Neutropenia</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Febrile neutropenia</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Thrombocytopenia</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Anaemia</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-haematological</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Nausea</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Vomiting</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Diarrhoea</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Elevated level of alanine aminotransferase</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;ILD-like syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Fever</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Rash</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Stomatitis/mucositis</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><p>Treatment was generally well tolerated in both arms. Patients receiving gemcitabine plus erlotinib experienced a significantly higher frequency of rash (64% <italic>vs</italic>. 2%, <italic>P</italic> &#x0003c; 0.001), but these were generally grade 1 or 2. The incidence of other adverse events, including hematologic toxicity and elevations in alanine aminotransferase, were similar between groups. There were no protocol-related deaths. One patient in the gemcitabine plus erlotinib group had interstitial lung disease (ILD)-like syndrome possibly related to therapy.</p><p>The gemcitabine dose intensity was similar in the gemcitabine alone and gemcitabine plus erlotinib groups (905 &#x000b1; 182 mg&#x02022;m<sup>&#x02212;2</sup>&#x02022;dose<sup>&#x02212;1</sup> &#x000d7; 8.2 &#x000b1; 5.5 doses <italic>vs</italic>. 881 &#x000b1; 236 mg&#x02022;m<sup>&#x02212;2</sup>dose<sup>&#x02212;1</sup> &#x000d7; 17.1 &#x000b1; 13.4 doses). Four (9%) patients receiving erlotinib and gemcitabine had at least one dose reduction of their oral agent. The erlotinib dose intensity was 96.8 &#x000b1; 12.6 mg&#x02022;m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup> &#x000d7; 17.9 &#x000b1; 13.7 weeks.</p></sec><sec id="s2_8"><title>Skin rash and survival in the gemcitabine plus erlotinib group</title><p>Of the 44 patients receiving gemcitabine plus erlotinib, 16 had no rash, 17 had grade 1 rash, 7 had grade 2 rash, 3 had grade 3 rash, and 1 had grade 4 rash. Patients with <italic>EGFR</italic> mutations did not have a significantly different rate of skin rash than patients without <italic>EGFR</italic> mutations (73% <italic>vs</italic>. 50%; <italic>P</italic> = 0.118). The presence of rash was associated with significantly higher rates of disease control (75% <italic>vs</italic>. 44%; <italic>P</italic> = 0.038) and treatment response (29% <italic>vs</italic>. 0%; <italic>P</italic> = 0.036). Patients with skin rash had significantly longer PFS (6.4 months; 95% CI, 4.1 to 8.7 months <italic>vs</italic>. 2.4 months; 95% CI, 0.8 to 4.0 months; <italic>P</italic> = 0.006, Figure <xref ref-type="fig" rid="F5">5A</xref>) and OS (8.6 months; 95% CI, 6.1 to 11.0 months vs. 5.8 months; 95% CI, 3.1 to 8.6 months; <italic>P</italic> = 0.043, Figure <xref ref-type="fig" rid="F5">5B</xref>).</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Skin rash and survival in the gemcitabine plus erlotinib group</title><p><bold>A.</bold> progression-free survival <bold>B.</bold> overall survival.</p></caption><graphic xlink:href="oncotarget-06-18162-g005"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p><italic>EGFR</italic> mutations are known to be the most important determinants of NSCLC patient response to EGFR-TKIs [<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R14" ref-type="bibr">14</xref>]. However, the importance of <italic>EGFR</italic> mutations in pancreatic cancer has not been investigated until now. The <italic>EGFR</italic> mutation profile in the Chinese population analyzed in this study can be used to predict treatment response and survival in pancreatic cancer patients receiving gemcitabine plus erlotinib.</p><p>The NCIC CTG PA.3 trial demonstrated the beneficial effects of erlotinib in the treatment of pancreatic cancer [<xref rid="R3" ref-type="bibr">3</xref>]. However, no Chinese patients were included in that study and the prolongation of median OS with erlotinib was only slightly longer, at 0.33 months. Neither EGFR protein expression status nor gene copy number was identified as a marker predictive of survival benefit following combination treatment with erlotinib and gemcitabine [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. In the present study, we used direct sequencing to detect <italic>EGFR</italic> mutations and confirmed by next-generation sequencing, which accurately predicted treatment response and survival in Chinese pancreatic cancer patients.</p><p>The median OS of patients treated with gemcitabine plus erlotinib (regardless of <italic>EGFR</italic> mutations) was 7.2 months. The NCIC CTG PA.3 trial, which included both locally advanced pancreatic cancer and metastatic pancreatic cancer patients, showed that the median OS with gemcitabine plus erlotinib was 6.24 months [<xref rid="R3" ref-type="bibr">3</xref>]. The more favorable outcome is likely because of the higher rate of <italic>EGFR</italic> mutations in this study [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R20" ref-type="bibr">20</xref>], which enhanced treatment efficacy [<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>]. These results are encouraging, especially because all patients were already in the metastatic stage.</p><p>The median survival with gemcitabine alone in this trial (4.4 months) is lower than that found by Burris et al. (5.65 months) [<xref rid="R2" ref-type="bibr">2</xref>], Moore et al. (5.91 months) [<xref rid="R3" ref-type="bibr">3</xref>], Conroy et al. (FOLFIRINOX, 6.8 months) [<xref rid="R4" ref-type="bibr">4</xref>], and the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT, 6.6 months) [<xref rid="R5" ref-type="bibr">5</xref>]. In this trial, the disease control rate with gemcitabine alone (25%) is also lower than that in the gemcitabine arms of the above trials (Burris et al., 44.4%; Moore et al., 49.2%; FOLFIRINOX, 50.9%; MPACT, 33%) [<xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R5" ref-type="bibr">5</xref>]. Our results are similar to another study of patients of Chinese descent (median survival 4 months) [<xref rid="R21" ref-type="bibr">21</xref>]. Other than ethnic differences, advanced age (median age 70 years in this study vs. 61-64 years in other studies) and advanced stage (all stage IV) may also account for the relatively poor survival and lower disease control rate in the gemcitabine alone group in this study.</p><p>In NSCLC and breast cancer, the prevalence of <italic>EGFR</italic> mutations between Caucasian and Asian patients is different [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R22" ref-type="bibr">22</xref>]. For NSCLC, there are variations between Chinese and other Asian populations [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>]. Lynch et al. did not detect any mutations in <italic>EGFR</italic> exons 19 and 21 in 40 pancreatic cancer primary tumors in Caucasian patients [<xref rid="R9" ref-type="bibr">9</xref>]. Tzeng et al. reported that 6/9 pancreatic cancer cell lines and 25/31 Caucasian pancreatic cancer patients had <italic>EGFR</italic> mutations, but all were silent mutations [<xref rid="R20" ref-type="bibr">20</xref>]. Oh et al. and Lee et al. showed a rate of 1.5&#x02013;2.5% <italic>EGFR</italic> mutations in Korean pancreatic cancer cohorts [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R25" ref-type="bibr">25</xref>]. However, none of these patients was Chinese. Our study was conducted in Taiwan, where the majority of the population is of Chinese descent, and the pancreatic cancer <italic>EGFR</italic> mutation rate was 56%. Improvement in OS for pancreatic cancer patients treated with erlotinib was apparent in our study because of the high proportion of cases with <italic>EGFR</italic> mutations compared to other studies. Currently, pancreatic cancer is the 7th leading cause of cancer death among the Chinese, making <italic>EGFR</italic> mutation detection an important issue in the treatment of pancreatic cancer [<xref rid="R26" ref-type="bibr">26</xref>].</p><p>The mutation sites in Chinese pancreatic cancer patients are also different from those reported in other populations [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R25" ref-type="bibr">25</xref>]. The presence of <italic>EGFR</italic>-activating mutations in Chinese patients emphasizes ethnic, geographic, and environmental variations in pancreatic cancer mutation profiles that could result in different responses to erlotinib treatment. Similar to reports by Tzeng et al. and Lee et al., we found Q787Q to be the most common silent mutation [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R20" ref-type="bibr">20</xref>]. In addition, we found four silent mutations that have not yet been reported, suggesting that <italic>EGFR</italic> silent mutations may vary among ethnicities.</p><p>The pattern of <italic>EGFR</italic> mutations varies among different solid tumors. In NSCLC, missense L858R and in-frame deletion E746_A750del constitute 78.2% of mutations [<xref rid="R27" ref-type="bibr">27</xref>]. All mutations in exon 19 (7.3%) were in-frame deletions (E746_A750del) in the squamous cell carcinoma of the head and neck [<xref rid="R28" ref-type="bibr">28</xref>], whereas two types of deletions, K745_E749del and E746_A750del, were found in exon 19 in cholangiocarcinomas [<xref rid="R29" ref-type="bibr">29</xref>]. Substitutions in exons 19 (E749K) and 20 (E762G and A767T) were predominant in 12% of colorectal carcinomas [<xref rid="R30" ref-type="bibr">30</xref>]. All of these mutations are different from those found in our work. Owing to these differences in the mutation profiles of <italic>EGFR</italic> for pancreatic cancer, compared with other cancers, commercially available <italic>EGFR</italic> mutation detection kits cannot replace direct sequencing [<xref rid="R31" ref-type="bibr">31</xref>].</p><p>Erlotinib-mediated disease control in <italic>EGFR</italic>-mutated pancreatic cancer patients is modest, with many patients achieving stable disease (85%). This is similar to the observations of Kwak et al. [<xref rid="R19" ref-type="bibr">19</xref>] who showed that both pancreatic cancer patients with <italic>EGFR</italic> mutations exhibited disease stabilization in response to therapy with erlotinib and capecitabine; however, this result does not fall within the same category of dramatic responses seen in NSCLC [<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R14" ref-type="bibr">14</xref>]. Further investigation is required to determine whether the site of primary cancer accounts for the disparate effects of TKI.</p><p>The gemcitabine plus erlotinib group had a higher disease control rate than the gemcitabine alone group for patients with an L778P mutation. Other mutation sites failed to demonstrate a significant difference in response and disease control rates. Because of their rarity, it is difficult to draw definitive conclusions regarding the true relationship between uncommon <italic>EGFR</italic> mutations and sensitivity to erlotinib. Further studies with larger patient numbers and functional analysis of the <italic>EGFR</italic> mutations are warranted to elucidate the impact of the individual mutation sites on the efficacy of erlotinib use.</p><p>There was no correlation between <italic>KRAS</italic> and <italic>EGFR</italic> mutations in our study, unlike the case in lung cancer, where these are generally mutually exclusive [<xref rid="R32" ref-type="bibr">32</xref>]. Furthermore, <italic>KRAS</italic> mutation status did not predict how patients would respond to erlotinib in our study, which is in line with the pivotal PA.3 study [<xref rid="R17" ref-type="bibr">17</xref>]. The small numbers of patients in our study (5.7%) who had wild-type KRAS make comparisons difficult with data from other randomized trials.</p><p>Most adverse events associated with erlotinib plus gemcitabine treatment in this study were mild-to-moderate, consistent with previous studies [<xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R5" ref-type="bibr">5</xref>]. Rash was more frequent with erlotinib plus gemcitabine than with gemcitabine alone, and we observed the association between rash and a better outcome that has been seen in other pancreatic cancer studies of EGFR inhibitors [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R33" ref-type="bibr">33</xref>, <xref rid="R34" ref-type="bibr">34</xref>]. One patient in the gemcitabine plus erlotinib arm had ILD-like syndrome. Gemcitabine and EGFR TKIs are both known to cause ILD-like syndrome, and it is possible that there is a more-than-additive effect when these agents are combined [<xref rid="R35" ref-type="bibr">35</xref>]. The incidence seen in this study (2.3%) is similar to that in other trials with combined gemcitabine and erlotinib [<xref rid="R3" ref-type="bibr">3</xref>].</p><p>FOLFIRINOX (a multidrug regimen of fluorouracil, leucovorin, irinotecan, and oxaliplatin) showed an increased median survival of 4.3 months but a worse safety profile compared to treatment with gemcitabine [<xref rid="R4" ref-type="bibr">4</xref>]. In another phase III multinational MPACT study, the combination of gemcitabine and nab-paclitaxel was shown to be superior to gemcitabine monotherapy, with a 1.8-month increase in median survival [<xref rid="R5" ref-type="bibr">5</xref>]. Combination therapy with gemcitabine plus erlotinib, gemcitabine plus nab-paclitaxel, or leucovorin, fluorouracil, irinotecan, and oxaliplatin is now considered first-line chemotherapy for metastatic pancreatic cancer.</p><p>Pancreatic cancer tends to be relatively resistant to chemotherapy and targeted therapy [<xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R8" ref-type="bibr">8</xref>], and only a few regimens have proven efficacious [<xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R36" ref-type="bibr">36</xref>]. Our study first found that <italic>EGFR</italic> mutations are common in Chinese pancreatic cancer patients. In addition, this study showed that <italic>EGFR</italic> mutations can predict gemcitabine plus erlotinib treatment response and survival. However, this study did have some limitations. First, the sample size of 88 participants is relatively small. However, a strong association was still detected between <italic>EGFR</italic> mutations and the efficacy of erlotinib in pancreatic cancer. Second, all enrollees were Chinese, and these results might not apply to other ethnicities. These issues require further investigation in additional larger clinical studies.</p><p>In conclusion, this is the first study to show a significant association between <italic>EGFR</italic> mutations and survival benefit in metastatic pancreatic cancer patients receiving erlotinib combined with gemcitabine. Detection of <italic>EGFR</italic> mutations can be used to identify the subgroup of patients with pancreatic cancer in whom <italic>EGFR</italic> may be essential for tumor growth and who would thus benefit from treatment with erlotinib.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Patient selection</title><p>This study was a single-center, randomized, open-label, prospective phase II trial. Inclusion criteria were metastatic pancreatic adenocarcinoma, presence of at least one measureable lesion, Eastern Cooperative Oncology Group (ECOG) performance status &#x02264; 2, absolute neutrophil count &#x02265; 1,500/mm<sup>3</sup>, platelet count &#x02265; 100,000/mm<sup>3</sup>, serum creatinine level &#x02264; 1.5&#x000d7; upper normal limit, aspartate aminotransferase or alanine aminotransferase level &#x02264; 5&#x000d7; upper normal limit, adequate samples for histological and mutational analyses, and absence of any other malignancy or serious medical or psychological illness that would preclude informed consent.</p></sec><sec id="s4_2"><title>Ethics statement</title><p>Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the Institutional Review Board of Taipei Veterans General Hospital, conforms to CONSORT guidelines, and was registered as ClinicalTrial.gov NCT01608841.</p></sec><sec id="s4_3"><title>Randomization</title><p>Patients were randomly allocated in a 1:1 ratio to receive either gemcitabine (Gemzar <sup>&#x000ae;</sup>; Eli Lilly and Company, Indianapolis, IN, USA) plus erlotinib (Tarceva; OSI Pharmaceuticals, Farmingdale, NY, USA) or gemcitabine alone using a computerized random number function in Microsoft Excel (Microsoft, Redmond, WA, USA). A block randomization procedure was employed to ensure equal group allocation.</p></sec><sec id="s4_4"><title>Treatment</title><p>Gemcitabine 1,000 mg/m<sup>2</sup> was infused over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest in cycle 1, and on days 1, 8, and 15 in all subsequent 4-week cycles. Erlotinib was taken orally at 100 mg once a day. Treatment continued until disease progression or intolerable toxicity.</p></sec><sec id="s4_5"><title>Pathology review, buffy coat, and DNA preparation</title><p>Pathological specimens were obtained on initial diagnosis from sonography-guided (40 patients) or computed tomography-guided biopsy (15 patients), endoscopic biopsy (4 patients), open biopsy (9 patients), or pancreatectomy (20 patients). Tumor samples were obtained from primary pancreatic tumor (<italic>n</italic> = 44) or metastatic tissue (<italic>n</italic> = 44). All tissue sections were cut from formalin-fixed paraffin-embedded tumor blocks, and histological examination was performed by a pathologist (YCY) blinded to clinical information. All tumor regions were confirmed prior to DNA isolation. The buffy coat, representing the normal tissue and separated using Histopaque solution (Histopaque-1119; Sigma-Aldrich, St. Louis, MO, USA), was obtained from all patients at enrollment. DNA was extracted from sections and the buffy coat using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany).</p></sec><sec id="s4_6"><title>Polymerase chain reaction (PCR) and sequencing of the EGFR gene</title><p>Eight pairs of oligonucleotide primers were used to amplify exons 18&#x02013;21 of the <italic>EGFR</italic> gene using PCR as described previously (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>) [<xref rid="R9" ref-type="bibr">9</xref>]. The PCR products were extracted and purified from a 1.5% agarose gel using the QIAquick gel extraction kit (Qiagen) and sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit and the ABI PRISM 3700 DNA Analyzer (PE Applied Biosystems, Foster City, CA, USA). PCR amplicon sequences were compared with the <italic>EGFR</italic> cDNA sequence obtained from Genbank (accession no. GI:22022643) by using Mutation Surveyor&#x02122; 3.0 (SoftGenetics, State College, PA, USA) and manual review. All sequence variants were verified by reverse sequencing.</p></sec><sec id="s4_7"><title>Ion torrent deep-amplicon sequencing</title><p>To eliminate PCR artifacts and false positives, the GeneRead DNA FFPE kit was used to extract DNA. The DNA extracted from FFPE was used for multiplex PCR of a panel covering 18&#x02013;21 exons in the <italic>EGFR</italic> gene. Fragment libraries were constructed using DNA fragmentation, barcode and adaptor ligation, and library amplification, according to the manufacturer's instructions, as stipulated in the Ion Xpress Plus Fragment Library Kit (Life Technologies, Grand Island, NY, USA). Size distribution of the DNA fragments was analyzed using the Agilent Bioanalyzer with the High Sensitivity Kit (Agilent, Santa Clara, CA, USA). Template preparation, emulsion PCR, and Ion Sphere Particle (ISP) enrichment was performed using the Ion PGM Template OT2 200 Kit (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. The ISPs were loaded onto a 314 chip and sequenced using an Ion PGM Sequencing 200 Kit v2 (Life Technologies, Grand Island, NY, USA).</p></sec><sec id="s4_8"><title>Bioinformatics analysis</title><p>After a successful sequencing reaction, the raw signal data were analyzed using Torrent Suite v4.0.2. The pipeline includes signaling processing, base calling, quality score assignment, adapter trimming, PCR duplicate removal, read alignment to human genome19 reference, mapping quality QC, coverage analysis, and variant calling. After completion of the primary data analysis, lists of detected sequence variants (SNVs and INDELs) were compiled in the VCF (Variant call file) format. For downstream analysis, variants with a minimum coverage of 500 reads were selected.</p></sec><sec id="s4_9"><title>PCR and sequencing of the KRAS gene</title><p>The cobas<sup>&#x000ae;</sup> KRAS Mutation Test (Roche Diagnostics, Basel, Switzerland) was used according to the manufacturer's protocol [<xref rid="R37" ref-type="bibr">37</xref>]. Samples (50 ng of DNA) were aliquoted in 96-well plates, and negative and positive controls from the kit were added. Data were automatically processed by cobas<sup>&#x000ae;</sup> software.</p></sec><sec id="s4_10"><title>Evaluation of treatment response and safety</title><p>Objective tumor response was evaluated every 8 weeks or earlier for patients with suspected progression according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) [<xref rid="R38" ref-type="bibr">38</xref>]; responses were confirmed at least 28 days after the first documentation of a complete or partial response or stable disease. Images were blindly reviewed by a protocol-trained radiologist (RCL). Serial measurements of carbohydrate antigen 19-9 (CA19-9) were performed at baseline and every 4 weeks thereafter. Safety was monitored by assessing treatment-related adverse events and serious adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v3.0).</p></sec><sec id="s4_11"><title>Statistical analysis</title><p>A superiority test was conducted with the assumption that gemcitabine plus erlotinib would have a higher disease control rate [<xref rid="R3" ref-type="bibr">3</xref>], defined as the best overall response for complete or partial response or stable disease, than gemcitabine alone. The disease control rate was estimated as 30% in the gemcitabine alone group, and 60% in the gemcitabine plus erlotinib group [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R39" ref-type="bibr">39</xref>]. A sample size of 44 for each group was required for 80% power with 5% error (two-tailed) and 5% loss to follow-up [<xref rid="R40" ref-type="bibr">40</xref>]. Secondary outcome measures were response rate, progression-free survival (PFS), overall survival (OS), relation to <italic>EGFR</italic> and <italic>KRAS</italic> mutation status, and safety. PFS was defined as the time from random assignment to disease progression or death as a result of any cause. For patients alive without documented disease progression at the time of the analysis, PFS was censored at the time of the last tumor assessment. If no post-baseline assessment was performed, the date of random assignment plus 1 day was used as the censor date. OS was defined as the time from random assignment until death as a result of any cause, and patients alive at the time of the analysis were censored at the date of last contact. In the response rate analysis, patients without a post-baseline assessment were not assessed. PFS and OS were calculated using the Kaplan-Meier method and log-rank tests. The Student's t test or one-way analysis of variance was used to analyze continuous variables between groups. The association between skin rash, <italic>EGFR</italic> mutations, response rate, and disease control rate were compared using the Chi-square test or Fisher's exact test. Statistical analyses were performed using SPSS software (SPSS 21.0, SPSS Inc., Chicago, IL, USA). <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY MATERIALS FIGURE AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-06-18162-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e2372" position="anchor"/></supplementary-material></sec></body><back><ack><p>The study was assisted in part by the Division of Experimental Surgery of the Department of Surgery, Taipei Veterans General Hospital to CPL. We thank Miss I-Hsuan Tsai at the Research and Development, TVGH Lihpao Lab of Cancer Genomic Medicine, Lihpao Life Science. Co., Ltd. for assisting with the next-generation sequencing.</p></ack><fn-group><fn fn-type="conflict"><p><bold>COMPETING INTERESTS</bold></p><p>We declare that we have no conflicts of interest.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>The study was funded by Taipei Veterans General Hospital (V103C-201), the National Science Council (NSC 98-2314-B-075-029), the Research Foundation of Digestive Medicine, R.O.C. (10311), and the National Research Program for Biopharmaceutics of Taiwan (100CT202). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2014</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">24399786</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Modiano</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>2403</fpage><lpage>2413</lpage><pub-id pub-id-type="pmid">9196156</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Hamm</surname><given-names>J</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Hecht</surname><given-names>JR</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><etal/></person-group><article-title>Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1960</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">17452677</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Desseigne</surname><given-names>F</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Guimbaud</surname><given-names>R</given-names></name><name><surname>Becouarn</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>1817</fpage><lpage>1825</lpage><pub-id pub-id-type="pmid">21561347</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Hoff</surname><given-names>DD</given-names></name><name><surname>Ervin</surname><given-names>T</given-names></name><name><surname>Arena</surname><given-names>FP</given-names></name><name><surname>Chiorean</surname><given-names>EG</given-names></name><name><surname>Infante</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1691</fpage><lpage>1703</lpage><pub-id pub-id-type="pmid">24131140</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindler</surname><given-names>HL</given-names></name><name><surname>Ioka</surname><given-names>T</given-names></name><name><surname>Richel</surname><given-names>DJ</given-names></name><name><surname>Bennouna</surname><given-names>J</given-names></name><name><surname>Letourneau</surname><given-names>R</given-names></name><name><surname>Okusaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>256</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">21306953</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Benedetti</surname><given-names>J</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>O'Reilly</surname><given-names>EM</given-names></name><name><surname>Flynn</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205</article-title><source>J Clinic Oncol</source><year>2010</year><volume>28</volume><fpage>3605</fpage><lpage>3610</lpage></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>van de Velde</surname><given-names>H</given-names></name><name><surname>Karasek</surname><given-names>P</given-names></name><name><surname>Oettle</surname><given-names>H</given-names></name><name><surname>Vervenne</surname><given-names>WL</given-names></name><name><surname>Szawlowski</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer</article-title><source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source><year>2004</year><volume>22</volume><fpage>1430</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">15084616</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name><name><surname>Gurubhagavatula</surname><given-names>S</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Brannigan</surname><given-names>BW</given-names></name><etal/></person-group><article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2129</fpage><lpage>2139</lpage><pub-id pub-id-type="pmid">15118073</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paez</surname><given-names>JG</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Tracy</surname><given-names>S</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><etal/></person-group><article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1497</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">15118125</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Endoh</surname><given-names>H</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name></person-group><article-title>Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>8919</fpage><lpage>8923</lpage><pub-id pub-id-type="pmid">15604253</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>XL</given-names></name><name><surname>Li</surname><given-names>LY</given-names></name><name><surname>Zhang</surname><given-names>XT</given-names></name><name><surname>Wang</surname><given-names>MZ</given-names></name><name><surname>Feng</surname><given-names>RE</given-names></name><name><surname>Cui</surname><given-names>QC</given-names></name><etal/></person-group><article-title>Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>4289</fpage><lpage>4294</lpage><pub-id pub-id-type="pmid">15958609</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Zakowski</surname><given-names>M</given-names></name><name><surname>Doherty</surname><given-names>J</given-names></name><name><surname>Politi</surname><given-names>K</given-names></name><name><surname>Sarkaria</surname><given-names>I</given-names></name><etal/></person-group><article-title>EGF receptor gene mutations are common in lung cancers from &#x0201c;never smokers&#x0201d; and are associated with sensitivity of tumors to gefitinib and erlotinib</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>13306</fpage><lpage>13311</lpage><pub-id pub-id-type="pmid">15329413</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Tsao</surname><given-names>MS</given-names></name></person-group><article-title>Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>1219</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">16505443</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arteaga</surname><given-names>C</given-names></name></person-group><article-title>Targeting HER1/EGFR: a molecular approach to cancer therapy</article-title><source>Semin Oncol</source><year>2003</year><volume>30</volume><fpage>3</fpage><lpage>14</lpage></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Jang</surname><given-names>KT</given-names></name><name><surname>Ki</surname><given-names>CS</given-names></name><name><surname>Lim</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma</article-title><source>Cancer</source><year>2007</year><volume>109</volume><fpage>1561</fpage><lpage>1569</lpage><pub-id pub-id-type="pmid">17354229</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Cunha Santos</surname><given-names>G</given-names></name><name><surname>Dhani</surname><given-names>N</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name><name><surname>Chin</surname><given-names>K</given-names></name><name><surname>Ludkovski</surname><given-names>O</given-names></name><name><surname>Kamel-Reid</surname><given-names>S</given-names></name><etal/></person-group><article-title>Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3</article-title><source>Cancer</source><year>2010</year><volume>116</volume><fpage>5599</fpage><lpage>5607</lpage><pub-id pub-id-type="pmid">20824720</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Lim do</surname><given-names>H</given-names></name><name><surname>Jang</surname><given-names>KT</given-names></name><name><surname>Lim</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>YL</given-names></name><etal/></person-group><article-title>Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy</article-title><source>Mol Cancer Ther</source><year>2011</year><volume>10</volume><fpage>1993</fpage><lpage>1999</lpage><pub-id pub-id-type="pmid">21862683</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>EL</given-names></name><name><surname>Jankowski</surname><given-names>J</given-names></name><name><surname>Thayer</surname><given-names>SP</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Brannigan</surname><given-names>BW</given-names></name><name><surname>Harris</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>4283</fpage><lpage>4287</lpage><pub-id pub-id-type="pmid">16857803</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzeng</surname><given-names>CW</given-names></name><name><surname>Frolov</surname><given-names>A</given-names></name><name><surname>Frolova</surname><given-names>N</given-names></name><name><surname>Jhala</surname><given-names>NC</given-names></name><name><surname>Howard</surname><given-names>JH</given-names></name><name><surname>Buchsbaum</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer</article-title><source>Surgery</source><year>2007</year><volume>141</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">17383523</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Garrett</surname><given-names>CR</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Huo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas</article-title><source>Br J Cancer</source><year>2012</year><volume>107</volume><fpage>411</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">22782343</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>N</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations</article-title><source>Diagn Pathol</source><year>2011</year><volume>6</volume><fpage>118</fpage><pub-id pub-id-type="pmid">22132735</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TY</given-names></name><name><surname>Chiu</surname><given-names>CH</given-names></name><name><surname>Li</surname><given-names>LH</given-names></name><name><surname>Hsiao</surname><given-names>CY</given-names></name><name><surname>Tzen</surname><given-names>CY</given-names></name><name><surname>Chang</surname><given-names>KT</given-names></name><etal/></person-group><article-title>Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>3750</fpage><lpage>3757</lpage><pub-id pub-id-type="pmid">15897572</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Won</surname><given-names>YW</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>GK</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Lim</surname><given-names>KY</given-names></name><name><surname>Yoon</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations</article-title><source>J Clin Pathol</source><year>2011</year><volume>64</volume><fpage>947</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">21725039</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Sohn</surname><given-names>CH</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Zang</surname><given-names>DY</given-names></name><etal/></person-group><article-title>A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research</article-title><source>Invest New Drugs</source><year>2012</year><volume>30</volume><fpage>1164</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">21404106</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noormohammad</surname><given-names>SF</given-names></name><name><surname>Mamlin</surname><given-names>BW</given-names></name><name><surname>Biondich</surname><given-names>PG</given-names></name><name><surname>McKown</surname><given-names>B</given-names></name><name><surname>Kimaiyo</surname><given-names>SN</given-names></name><name><surname>Were</surname><given-names>MC</given-names></name></person-group><article-title>Changing course to make clinical decision support work in an HIV clinic in Kenya</article-title><source>International Journal of Medical Informatics</source><year>2010</year><volume>79</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">20089444</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name><name><surname>Shih</surname><given-names>JY</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Hu</surname><given-names>FC</given-names></name><name><surname>Tsai</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy</article-title><source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source><year>2008</year><volume>26</volume><fpage>2745</fpage><lpage>2753</lpage><pub-id pub-id-type="pmid">18509184</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Soung</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Nam</surname><given-names>HK</given-names></name><name><surname>Park</surname><given-names>WS</given-names></name><name><surname>Nam</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>2879</fpage><lpage>2882</lpage><pub-id pub-id-type="pmid">15837736</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gwak</surname><given-names>GY</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Shin</surname><given-names>CM</given-names></name><name><surname>Ahn</surname><given-names>YJ</given-names></name><name><surname>Chung</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas</article-title><source>J Cancer Res Clin Oncol</source><year>2005</year><volume>131</volume><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">16032426</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagahara</surname><given-names>H</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Ohta</surname><given-names>M</given-names></name><name><surname>Utsunomiya</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Barnard</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Somatic mutations of epidermal growth factor receptor in colorectal carcinoma</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>1368</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">15746034</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>CP</given-names></name><name><surname>Nowara</surname><given-names>E</given-names></name><name><surname>Aprile</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Federowicz</surname><given-names>I</given-names></name><etal/></person-group><article-title>Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study</article-title><source>Br J Cancer</source><year>2014</year><volume>111</volume><fpage>2067</fpage><lpage>2075</lpage><pub-id pub-id-type="pmid">25247318</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>TY</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><etal/></person-group><article-title>KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib</article-title><source>PLoS Med</source><year>2005</year><volume>2</volume><fpage>e17</fpage><pub-id pub-id-type="pmid">15696205</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Vervenne</surname><given-names>WL</given-names></name><name><surname>Bennouna</surname><given-names>J</given-names></name><name><surname>Humblet</surname><given-names>Y</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Van Laethem</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>2231</fpage><lpage>2237</lpage><pub-id pub-id-type="pmid">19307500</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinemann</surname><given-names>V</given-names></name><name><surname>Vehling-Kaiser</surname><given-names>U</given-names></name><name><surname>Waldschmidt</surname><given-names>D</given-names></name><name><surname>Kettner</surname><given-names>E</given-names></name><name><surname>Marten</surname><given-names>A</given-names></name><name><surname>Winkelmann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the &#x02018;Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)</article-title><source>Gut</source><year>2013</year><volume>62</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">22773551</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danson</surname><given-names>S</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name><name><surname>Hulse</surname><given-names>P</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name></person-group><article-title>Interstitial lung disease in lung cancer: separating disease progression from treatment effects</article-title><source>Drug Saf</source><year>2005</year><volume>28</volume><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">15691221</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Ioka</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Ohkawa</surname><given-names>S</given-names></name><name><surname>Yanagimoto</surname><given-names>H</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><etal/></person-group><article-title>Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>1640</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">23547081</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Brophy</surname><given-names>VH</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Velez</surname><given-names>M</given-names></name><name><surname>Hoeppner</surname><given-names>C</given-names></name><name><surname>Soviero</surname><given-names>S</given-names></name><etal/></person-group><article-title>Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma</article-title><source>Virchows Arch</source><year>2012</year><volume>460</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">22173329</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><etal/></person-group><article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">10655437</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>JP</given-names></name><name><surname>Lee</surname><given-names>RC</given-names></name><name><surname>Lee</surname><given-names>WP</given-names></name><name><surname>Li</surname><given-names>CP</given-names></name></person-group><article-title>A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>72</volume><fpage>637</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">23912692</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="web"><ext-link ext-link-type="uri" xlink:href="http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html">http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html</ext-link></element-citation></ref></ref-list></back></article>